Prussian Blue decorporation of 137Cs in beagles of different ages.
A 6-wk study was conducted using immature (4.7 mo), young adult (2.4 y), and aged (13.5 y) male beagles to determine the modifying effect of age on the effectiveness of Prussian Blue decorporation therapy for the removal of injected 137Cs. Whole-body clearance rates for injected 137Cs decreased with increasing age in the dogs. Treatment with Prussian Blue changed the ratio of fecal to urinary 137Cs excretion from 0.8 in untreated dogs to 2.2 in treated animals. The 137Cs concentrations in tissues of untreated and Prussian Blue-treated dogs at the end of the 6-wk study were similar, with the greatest concentrations in the skeletal muscle tissue, spleen, and kidneys. There was a lower concentration of 137Cs in the livers of the treated dogs. The reductions in the average total whole-body doses resulting from Prussian Blue treatment during the course of this study were 51% in the immature, 31% in the young adult, and 38% in the aged dogs. Because of the differences in the intake of Prussian Blue by the dogs in the different groups relative to their body weight, it is unclear as to the relative effectiveness of Prussian Blue in dogs of different ages.
Melo
D R
DR
Inhalation Toxicology Research Institute, Lovelace Biomedical and Environmental Research Institute, Albuquerque, NM 87185, USA.
Lundgren
D L
DL
Muggenburg
B A
BA
Guilmette
R A
RA
D000367:Age Factors; D000818:Animals; D000931:Antidotes / Q000627:therapeutic use*; D001822:Body Burden; D002588:Cesium Radioisotopes / Q000378:metabolism; D002614:Chelating Agents / Q000627:therapeutic use; D004285:Dogs; D005295:Ferrocyanides / Q000627:therapeutic use*; D008657:Metabolic Clearance Rate; D014018:Tissue Distribution
D000931:Antidotes; D002588:Cesium Radioisotopes; D002614:Chelating Agents; D005295:Ferrocyanides; C000170:ferric ferrocyanide